Full-Time
Associate Director
Global Omnichannel Solutions Delivery
Revolution Medicines
1,001-5,000 employees
Clinical-stage oncology company developing RAS inhibitors
Compensation Overview
$186k - $233k/yr
San Carlos, CA, USA
Hybrid
Bachelor's
 Business & Strategy (1) |
|---|
Get referred to Revolution Medicines
See people who can refer or advise you
- Ten or more years of experience implementing and managing marketing technologies, with a focus on omnichannel, digital ecosystems, or multi-platform environments.
- Experience delivering global or multi-region digital initiatives, including localization and regional deployment considerations.
- Demonstrated experience navigating regional variations in data privacy, consent management, and digital engagement compliance, including GDPR and relevant global regulations.
- Experience in the pharmaceutical or biotech industry, with understanding of healthcare regulations and digital compliance requirements.
- Demonstrated knowledge of digital ecosystem design, including system interoperability, data flows, platform scalability, and integration of third-party healthcare professional data sources such as OneKey and IQVIA/MIDAS into Omnichannel platforms.
- Experience working with or enabling AI-driven capabilities (e.g., personalization, content generation, or advanced analytics) within digital or marketing ecosystems.
- Strong stakeholder management and ability to work across cross-functional teams in a fast-paced environment.
- Highly organized with strong attention to detail and commitment to quality.
- Excellent communication, problem-solving, and collaboration skills.
- Bachelor’s degree or equivalent experience.
- Lead deployment of integrated customer journeys across ex-US markets, ensuring alignment with global platform strategy.
- Enable launch, medical, and global expansion priorities through scalable solution enablement.
- Ensure solutions are designed with global scalability in mind, enabling efficient expansion across brands, regions, and customer types.
- Proactively assess AI, automation, and other emerging technology trends to enable innovative, future-ready solutions that support evolving customer needs across markets.
- Collaborate with internal teams (e.g., Regional IT Leads, Global Medical Affairs, Global Commercialization) and external partners to deliver integrated omnichannel capabilities.
- Translate global and regional business requirements into scalable technical specifications and solution designs.
- Evaluate, select, and ensure new capabilities and solutions operate effectively across systems and geographies.
- Provide recommendations on capability sequencing, integration tradeoffs, and platform roadmap priorities.
- Establish and manage processes that deliver consistent, high-quality solutions across omnichannel systems.
- Prevent redundant or fragmented systems by promoting reuse, standardization, and alignment across teams.
- Maintain data integrity, quality control, and compliance across platforms and processes.
- Manage vendor and implementation partner performance, delivery quality, and budget-impacting activities related to global omnichannel enablement.
- Proven experience working across Marketing Cloud and Adobe Experience Manager.
- Experience managing external vendors and implementation partners.
- Experience working within both marketing operations and IT functions, with a strong understanding of cross-functional collaboration.
- Experience with Veeva Vault or Veeva CRM.
- Experience with an oncology launch.
- Experience with consent management platforms (e.g. OneTrust).
- Experience delivering field suggestions/next best action capabilities.
- Experience evaluating and selecting new technologies or capabilities.
Revolution Medicines develops targeted therapies for cancers caused by RAS mutations, which are found in about 30% of human cancers. The company’s products are small molecules called RAS(ON) inhibitors that work by blocking the active, cancer-promoting form of the RAS protein to stop tumor growth. Unlike older treatments that could only target a few specific mutations, this platform creates inhibitors that can address a much wider range of RAS-driven cancers. The company's goal is to advance these candidates through clinical trials to provide effective treatment options for patients with previously "undruggable" forms of cancer.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Redwood City, California
Founded
2014
Get referred to Revolution Medicines
See people who can refer or advise you
Simplify's Take
What believers are saying
- FDA accepted daraxonrasib NDA July 22, 2026, accelerating first commercial launch.
- BeOne will fund a global Phase 3, reducing Revolution's late-stage cash burden.
- Cash and marketable securities reached $3.9 billion on June 30, 2026, funding operations.
What critics are saying
- Daraxonrasib still depends on FDA approval after the August 2026 NDA acceptance.
- R&D burned $394.9 million in Q2 2026; cumulative losses reached $4.0 billion.
- If daraxonrasib disappoints in pancreatic launch or NSCLC readouts, Revolution loses its value anchor.
What makes Revolution Medicines unique
- Daraxonrasib delivered 13.2-month median OS in RASolute 302, versus 6.7 months chemotherapy.
- Revolution Medicines targets active RAS with RAS(ON) inhibitors across KRAS G12C, G12D, and G12V.
- The BeOne August 2026 deal validates its platform and extends regional commercialization reach.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Company Equity
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -3%2 year growth
↓ -4%Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.
BeOne Medicines and Revolution Medicines announce clinical development and Regional commercialization collaboration. Clinical collaboration enables novel combinations of select BeOne oncology assets with four Revolution Medicines clinical-stage RAS(ON) inhibitors for RAS-addicted cancers Regional rights agreement provides BeOne with exclusive development and commercialization rights to four Revolution Medicines clinical assets in select Asian markets SAN CARLOS, Calif. & REDWOOD CITY, Calif. - BeOne Medicines Ltd. (Nasdaq: ONC; HKEX:...
Revolution Medicines announced second quarter 2026 financial results, reporting cash and marketable securities of $3.9 billion as of 30 June. The company completed concurrent public offerings totalling $2.2 billion in gross proceeds and received $250 million from Royalty Pharma. The FDA accepted the company's new drug application for daraxonrasib to treat previously treated metastatic pancreatic cancer. Over 2,000 patients have received the drug through an expanded access programme since May. The FDA also granted breakthrough therapy designation for daraxonrasib in certain non-small cell lung cancer patients. Research and development expenses rose to $394.9 million from $224.1 million year-over-year, whilst general and administrative expenses increased to $110.2 million from $40.6 million. Net loss totalled $644.4 million, compared to $247.8 million in the prior year quarter.
Revolution Medicines: the attack on the unbreakable cancer code. Reading time: 3 minutes Revolution Medicines is developing novel active ingredients that specifically block the active form of cancer-driving RAS proteins, which were previously considered untreatable and are responsible for about a third of all cancers. With the advanced hopeful candidate Daraxonrasib, the company is filling a huge supply gap in difficult-to-treat tumors such as pancreatic and lung cancer. Thanks to strong capital partners, the transition from research to commercial provider is financially secured, nevertheless... Trader newspaper - order now for only 1 €. for 28 days Then 3 months duration Total price: 99,- € Price drop after China report: Technological advances of a state-funded Chinese competitor cause ASML to drop by 5.8%... July 27, 2026 could go down as a turning point in the history of quantum computing. Two pieces of news arrived simultaneously and fueled each other:...
Axsome Therapeutics and Revolution Medicines have delivered strong returns this year, with shares climbing 34% and 135% respectively in the first half. Both biotechnology companies attracted investors seeking growth opportunities beyond artificial intelligence. Axsome specialises in central nervous system disorders and has three marketed products. In the recent quarter, Auvelity sales rose 59% to $153 million, whilst Sunosi revenue increased 34% to $33 million. The company recently secured approval for Auvelity in treating Alzheimer's agitation and has five phase 3 programmes underway. Revolution Medicines, whilst earlier-stage with no commercialised products yet, has candidates in registrational trials for pancreatic cancer and non-small cell lung cancer treatment. The company recently announced positive phase 3 results for its lead oncology candidate.